Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

INCYTE CORPORATION

(INCY)
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su INCYTE CORPORATION
18/11Novartis Said Considering Takeover in Biotech Sector
11/11Morphosys bleibt in den roten Zahlen - Aktie unter Druck
10/11Morphosys bleibt in den roten Zahlen - Umsatz steigt aber
09/11Incyte to Present at Upcoming Investor Conference
08/11First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Stud..
05/11Mehr als 35 Abstracts aus dem Onkologie-Portfolio von Incyte auf der 63. ASH-Jahrestagu..
04/11More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at th..
04/11SEC Brings Insider Trading Out Of The Shadows
02/11INCYTE CORP Management's Discussion and Analysis of Financial Condition and Results of..
02/11Corporate Statement Regarding Opzelura™ (ruxolitinib) Cream - Form 8-K
02/11INCYTE CORP: Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
02/11Incyte Q3 Adjusted Earnings Surge as Revenue Rises
02/11INCYTE: Q3 Earnings Snapshot
02/11Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinica..
02/11Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinica..
02/11Earnings Flash (INCY) INCYTE Reports Q3 EPS $1.18, vs. Street Est of $0.75
02/11Incyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended..
01/11Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immu..
01/11Data from Incyte?s Oncology Portfolio Accepted for Presentation at the Society for Immu..
01/11Incyte Says FDA Accepts New Drug Application for Priority Review for Treating Two Forms..
01/11Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refra..
01/11Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refra..
28/10Incyte annonce la validation de la demande d'autorisation de commercialisation européen..
28/10European Medicines Agency Validates Incyte's Marketing Authorization Application For Ru..
28/10Incyte kündigt Validierung des europäischen Zulassungsantrags für Ruxolitinib-Creme bei..
28/10Incyte Announces the Validation of the European Marketing Authorization Application for..
28/10Incyte Announces the Validation of the European Marketing Authorization Application for..
22/10Lymphoma Hub maintains its focus on raising the levels of global knowledge of lymphoma ..
22/10INCYTE: Named to Newsweek's List of America's Most Loved Workplaces for 2021
22/10INCYTE: Signs Distribution Deal for Cancer Therapies With Specialised Therapeutics for Au..
19/10WALL STREET: entame bien novembre malgré taux et baril à 83$
15/10GVHD HUB IN Q3: Boosting levels of knowledge in the graft-versus-host disease setting
13/10INCYTE: to Report Third Quarter Financial Results
06/10BRIACELL THERAPEUTICS: October is Breast Cancer Awareness Month - BriaCell is Advancing t..
05/10VISIÓN GENERAL DE LOS ETF: Apueste por las apuestas deportivas y el iGaming
04/10INCYTE: annonce les résultats complets de son programme TRuE-V de Phase 3 évaluant la crè..
03/10INCYTE: gibt vollständige Ergebnisse des Phase-3-Programms TRuE-V zu Ruxolitinib-Creme (O..
02/10INCYTE: Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (..
02/10Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream ..
30/09ELI LILLY AND: Incyte Say Olumiant Improved Hair Regrowth in Studies to Treat Alopecia Ar..
30/09ELI LILLY: les promesses de l'Olumiant dans l'alopécie
30/09INCYTE: OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as ..
30/09Eli Lilly and Company and Incyte Announces Detailed Results from Two Pivotal Phase 3 Tr..
30/09LILLY, INCYTE: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks
28/09INCYTE: Names New Member to Its Board of Directors
28/09INCYTE CORP: Change in Directors or Principal Officers (form 8-K)
28/09Incyte Corporation Elects Otis W. Brawley Member of the Board of Directors
28/09NORTH AMERICAN MORNING BRIEFING: Stock Futures -3-
27/09Health Care Stocks Trade Lower Pre-Bell Monday
27/09SYNDAX PHARMACEUTICALS: Health Care
27/09SYNDAX PHARMACEUTICALS: Signs Multi-Million Dollar Deal With Incyte to Develop Treatment ..
27/09Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commerci..
27/09INCYTE CORPORATION ENTERED INTO STOC: SNDX) for $35 million.
24/09Syndax Pharmaceuticals, Inc. announced that it expects to receive $34.997896 million in..
23/09INCYTE: Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America
23/09KNIGHT THERAPEUTICS: in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasi..
23/09KNIGHT THERAPEUTICS BRIEF: Enters into Exclusive Supply and Distribution Agreement with N..
23/09INCYTE: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with ..
23/09INCYTE: SEC Charges Former Executive With Insider Trading On A Misappropriation Theory&md..
22/09Health Care Stocks Pare Gains in Late Wednesday Trade
22/09INCYTE: Gets FDA Approval for Graft-Versus-Host Disease Treatment Jakafi
22/09INCYTE: Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Ve..
22/09Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-V..
22/09Incyte Says FDA Approves Jakafi in Chronic Graft-Versus-Host Disease
22/09Fed verdict is imminent
22/09Incyte Corporation Provides Revenue Guidance for the Year 2022
21/09INCYTE: FDA approves Incyte's eczema cream with boxed warnings
21/09INCYTE: Atopic Dermatitis Treatment Receives US FDA Approval
21/09INCYTE: FDA approves Incyte's eczema cream
21/09INCYTE: Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK..
21/09Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhi..
17/09INCYTE: Secures Conditional Approval From Health Canada for Bile Duct Cancer Treatment
17/09INCYTE: Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First ..
17/09Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First..
16/09MACROGENICS: Reports Partial Data From Margetuximab Combo Trial in Gastroesophageal Cance..
1  2  3  4  5  6  7  8  9  10Pross.
Prossimo evento su INCYTE CORPORATION
30/11/21
Prossimi eventi del settore